BiotechTube
Home/ImmunityBio/Rich Adcock
RA

Rich Adcock

President & Chief Executive Officer

ImmunityBio

Therapeutic Areas

OncologyBladder CancerLung CancerGlioblastomaOvarian CancerNon-Hodgkin LymphomaHIVHead and Neck CancerLynch Syndrome

ImmunityBio Pipeline

DrugIndicationPhase
ANKTIVA® + BCGBCG-Unresponsive NMIBC CISApproved
ANKTIVA® + TislelizumabNon-Small Cell Lung CancerPhase 3
ANKTIVA® + bevacizumab + PD-L1 t-haNKRecurrent/Progressive GlioblastomaPhase 2
ANKTIVA® + M-ceNKPlatinum-Resistant Ovarian CancerPhase 2
ANKTIVA® + CD19 t-haNKRelapsed/Refractory Non-Hodgkin LymphomaPhase 1
ANKTIVA® + Tri-Ad5 vaccinesLynch SyndromePhase 2
ANKTIVA® + Ad5 HPVHPV+ Head & Neck CancerPhase 1
ANKTIVA®HIV/AIDSPhase 1

Leadership Team at ImmunityBio

DP
Dr. Patrick Soon-Shiong
Executive Chairman and Global Chief Scientific and Medical Officer
DH
Dr. Hans Klingemann
Key Scientific Contributor - NK-92 Cell Line Developer
DS
Dr. Sam Chang
Study Investigator and Urologic Oncologist
View full ImmunityBio profile